Risk Factor Analysis for Secondary Malignancy in Dexrazoxane-Treated Pediatric Cancer Patientsopen access
- Authors
- Kim, Hyery; Kang, Hyoung Jin; Park, Kyung Duk; Koh, Kyung-Nam; Im, Ho Joon; Seo, Jong Jin; Lee, Jae Wook; Chung, Nack-Gyun; Cho, Bin; Kim, Hack Ki; Lee, Jae Min; Hah, Jeong Ok; Lee, Jun Ah; Lee, Young Ho; Park, Sang Kyu; Baek, Hee Jo; Kook, Hoon; Kim, Ji Yoon; Kim, Heung Sik; Kim, Hwang Min; Chueh, Hee Won; Park, Meerim; Yoon, Hoi Soo; Lee, Mee Jeong; Choi, Hyoung Soo; Ahn, Hyo Seop; Kawano, Yoshifumi; Park, Ji Won; Hahn, Seokyung; Shin, Hee Young
- Issue Date
- Jan-2019
- Publisher
- KOREAN CANCER ASSOCIATION
- Keywords
- Dexrazoxane; Childhood; Cancer; Anthracyclines; Risk factors; Second neoplasm
- Citation
- CANCER RESEARCH AND TREATMENT, v.51, no.1, pp 357 - 367
- Pages
- 11
- Journal Title
- CANCER RESEARCH AND TREATMENT
- Volume
- 51
- Number
- 1
- Start Page
- 357
- End Page
- 367
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/74879
- DOI
- 10.4143/crt.2017.457
- ISSN
- 1598-2998
2005-9256
- Abstract
- Purpose Dexrazoxane has been used as an effective cardioprotector against anthracycline cardiotoxicity. This study intended to analyze cardioprotective efficacy and secondary malignancy development, and elucidate risk factors for secondary malignancies in dexrazoxane-treated pediatric patients. Materials and Methods Data was collected from 15 hospitals in Korea. Patients who received any anthracyclines, and completed treatment without stem cell transplantation were included. For efficacy evaluation, the incidence of cardiac events and cardiac event-free survival rates were compared. Data about risk factors of secondary malignancies were collected. Results Data of total 1,453 cases were analyzed; dexrazoxane with every anthracyclines group (D group, 1,035 patients) and no dexrazoxane group (non-D group, 418 patients). Incidence of the reported cardiac events was not statistically different between two groups; however, the cardiac event-free survival rate of patients with more than 400 mg/m(2) of anthracyclines was significantly higher in D group (91.2% vs. 80.1%, p=0.04). The 6-year cumulative incidence of secondary malignancy was not different between both groups after considering follow-up duration difference (non-D, 0.52%+/- 0.37%; D, 0.60%+/- 0.28%; p=0.55). The most influential risk factor for secondary malignancy was the duration of anthracycline administration according to multivariate analysis. Conclusion Dexrazoxane had an efficacy in lowering cardiac event-free survival rates in patients with higher cumulative anthracyclines. As a result of multivariate analysis for assessing risk factors of secondary malignancy, the occurrence of secondary malignancy was not related to dexrazoxane administration.
- Files in This Item
-
- Appears in
Collections - ETC > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/74879)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.